Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025560 | 0.83 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL267839 | 0.82 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL3267444 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL30879956 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL2913941 | 0.81 | PDE10A (0.61) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL4938792 | 0.79 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL3028085 | 0.78 | PDE10A (0.46) | CYSLTR1CYSLTR2CYP1A2PDE10A | |
| SCHEMBL3294465 | 0.77 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL153778 | 0.77 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL6798820 | 0.77 | CYSLTR2 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63190886-A | — | — | None | — | — | JP | disclosed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| EP-1193265-B1 | A process for the preparation of 4-¬2-(aryl or heterocyclo)-1H-imidazol-1-yl|benzenesulfonamides | SEARLE LLC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | disclosed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | disclosed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | disclosed |
| EP-0880504-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | disclosed |
| EP-1193265-A2 | A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides | G.D. Searle & Co. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| JP-S63190886-A | 2-AMINO-1,3,4-THIADIAZOLE DERIVATIVE AND ANTIULCER AGENT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | TSUMURA & CO | 1988-08-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | LTC4S, HRH4, LTB4R2 | CYSLTR1 8/4885CYSLTR2 6/4885CYP1A2 921/4885 |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | CYSLTR1 10/4885CYSLTR2 6/4885CYP1A2 1041/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | CYSLTR1 14/4885CYSLTR2 9/4885CYP1A2 947/4885 |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | CYSLTR1 147/4885CYSLTR2 392/4885CYP1A2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.